---
title: "Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289044671.md"
description: "Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock News"
datetime: "2026-06-08T03:05:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289044671.md)
  - [en](https://longbridge.com/en/news/289044671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289044671.md)
generator: "portal-rs"
---

# Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock News

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock News

### Related Stocks

- [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md)

## Related News & Research

- [Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading](https://longbridge.com/en/news/297066497.md)
- [Seaport Therapeutics Q2 FY26 net loss widens to $62.6 million; R&D expenses rise to $24.62 million](https://longbridge.com/en/news/294682349.md)
- [Nykode Therapeutics announces availability of Q2 2026 financial results report](https://longbridge.com/en/news/297025454.md)
- [Nykode Therapeutics to release Q2 financial results, host webcast presentation](https://longbridge.com/en/news/296641436.md)
- [Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of common shares worth $2.51 million](https://longbridge.com/en/news/297082004.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**